INCA036873 for adults with advanced solid tumors and blood cancers.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial tests INCA036873 in adults with advanced solid tumors and selected hematologic malignancies, including clear cell renal cell carcinoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma. Eligible participants must have measurable disease, an ECOG performance status of 0–1, available tumor tissue for central testing, and disease progression after specified prior therapies. The study will use dose-escalation cohorts to define safety and tolerability and may open expansion cohorts once a recommended dose is identified. The trial is sponsored by Incyte Corporation and is enrolling at academic centers in California and Michigan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* ECOG performance status of 0 or 1.
* Histologically confirmed:

  * Clear cell renal cell carcinoma (ccRCC).
  * Diffuse large B-cell lymphoma (DLBCL, NOS).
  * High-grade B-cell lymphoma (HGBCL).
  * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
  * Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
* Disease progression, relapse, or refractory to prior therapy:

  * ccRCC: ≥1 prior line incl. ICI + TKI.
  * DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
  * PTCL/CTCL: ≥1 prior systemic therapy.
* Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
* Tumor tissue available for central testing.

Exclusion Criteria:

* Untreated or progressive CNS disease unless previously treated and stable.
* Other active invasive malignancy within 2 years (except certain low-risk cancers).
* Prior CD70-targeting therapy, including CAR T.
* ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
* Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
* Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
* Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
* Pregnancy, breastfeeding, or unwillingness to use effective contraception.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting
• University of California San Diego Medical Center, Moores Cancer Center
  La Jolla, California, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting
• The University of Nebraska Medical Center
  Omaha, Nebraska, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• Scri Oncology Partners
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Incyte Corporation Call Center (US)
• Email: medinfo@incyte.com
• Phone: 1.855.463.3463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term evaluation of pembrolizumab for patients with advanced tumors

  This study is testing how well pembrolizumab works and how safe it is for people with advanced tumors who have already been part of previous studies.

  Recruiting at 472 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 781 other locations · NCT03486873

• Mayo Clinic radiotherapy outcomes registry and biobank

  This project collects blood and tissue from people with solid tumors or blood cancers treated with photon or proton radiotherapy at Mayo Clinic Rochester to see if biological markers link to side effects and outcomes.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT02457962

• BA1203 in advanced solid tumors: safety and early signs of activity

  This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing · NCT07876609

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• REC-7735 for PIK3CA-H1047R-mutant solid tumors

  This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.

  Recruiting at 3 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Grand Rapids, Michigan and 2 other locations · NCT07819136

• Preferences of physicians and patients for cell therapies in advanced solid tumors

  This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.

  Recruiting Zhejiang University · Hangzhou, Zhejiang · NCT07813000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.